Skip to main content

Advertisement

SpringerLink
Log in

Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine

  • Genetic Epidemiology (C Amos, Section Editor)
  • Published:
Current Epidemiology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The goal of this review is to highlight emerging biomarker research by the key phases of the cancer continuum and outline the methodological considerations for biomarker application.

Recent Findings

While biomarkers have an established role in targeted therapy and, to some extent, disease monitoring, their role in early detection and survivorship remains to be elucidated. With the advent of omics technology, the discovery of biomarkers has been accelerated exponentially, therefore careful consideration to ensure an unbiased study design and robust validity is crucial.

Summary

The rigor of biomarker research holds the key to the success of precision health care. The potential clinical utility and the feasibility of implementation should be central to future biomarker research study design.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC): National Academies Press (US); 2011.

  2. Lethimonnier F, Levy Y. Genomic medicine France 2025. Ann Oncol. 2018;29:783–4.

    Article  CAS  PubMed  Google Scholar 

  3. Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, Halai D, Baple E, Craig C, Hamblin A, Henderson S, Patch C, O’Neill A, Devereau A, Smith K, Martin AR, Sosinsky A, McDonagh EM, Sultana R, Mueller M, Smedley D, Toms A, Dinh L, Fowler T, Bale M, Hubbard T, Rendon A, Hill S, Caulfield MJ, Genomes P. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018;361:k1687.

    Article  PubMed  Google Scholar 

  4. Beane J, Campbell JD, Lel J, Vick J, Spira A. Genomic approaches to accelerate cancer interception. Lancet Oncol. 2017;18:e494–502.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Penney, KL., Michailidou, K., Carere, DA., Zhang, C., Pierce, B., Lindstrom, S. Kraft, P. in Schottenfeld and Fraumeni cancer epidemiology and prevention, 4th Edition. (eds M. J. Thun et al.) Ch. 5, 53–76 (Oxford University Press, 2018).

  6. Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392–406

  7. Plym, A., Penney, KL., Kalia, S., Kraft, P., Conti, DV., Haiman, C., Mucci, LA. Kibel, AS. Evaluation of a multiethnic polygenic risk score model for prostate cancer. J Natl Cancer Inst (2021).

  8. Hung, RJ., Warkentin, MT., Brhane, Y., Chatterjee, N., Christiani, DC., Landi, MT., Caporaso, NE., Liu, G., Johansson, M., Albanes, D., Marchand, LL., Tardon, A., Rennert, G., Bojesen, SE., Chen, C., Field, JK., Kiemeney, LA., Lazarus, P., Zienolddiny, S., Lam, S., Andrew, AS., Arnold, SM., Aldrich, MC., Bickeboller, H., Risch, A., Schabath, MB., McKay, JD., Brennan, P. Amos, CI. Assessing lung cancer absolute risk trajectory based on a polygenic risk model. Cancer Res 81, 1607–1615 (2021).

  9. Mars, N., Widen, E., Kerminen, S., Meretoja, T., Pirinen, M., Della Briotta Parolo, P., Palta, P., FinnGen, Palotie, A., Kaprio, J., Joensuu, H., Daly, M. Ripatti, S. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat Commun 11, 6383 (2020).

  10. Pal Choudhury, P., Brook, MN., Hurson, AN., Lee, A., Mulder, CV., Coulson, P., Schoemaker, MJ., Jones, ME., Swerdlow, AJ., Chatterjee, N., Antoniou, AC. Garcia-Closas, M. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Res 23, 22 (2021).

  11. NCCN guidelines for genetics/familial high-risk assessment: breast, ovarian and pancreatic V.1.2022. National Comprehensive Cancer Network. (2021).

  12. Polygenic Risk Score Task Force of the International Common Disease, A. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nature medicine 27, 1876–1884 (2021).

  13. Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK. Biomarkers of tobacco exposure: summary of an FDA-sponsored public workshop. Cancer Epidemiol Biomarkers Prev. 2017;26:291–302.

    Article  CAS  PubMed  Google Scholar 

  14. Stram DO, Park SL, Haiman CA, Murphy SE, Patel Y, Hecht SSL, Marchand L. Racial/ethnic differences in lung cancer incidence in the multiethnic cohort study: an update. J Natl Cancer Inst. 2019;111:811–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kaur G, Begum R, Thota S, Batra S. A systematic review of smoking-related epigenetic alterations. Arch Toxicol. 2019;93:2715–40.

    Article  CAS  PubMed  Google Scholar 

  16. Park SL, Patel YM, Loo LWM, Mullen DJ, Offringa IA, Maunakea A, Stram DO, Siegmund K, Murphy SE, Tiirikainen M. Le, Marchand L. Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics. 2018;10:110.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Prince C, Hammerton G, Taylor AE, Anderson EL, Timpson NJ, Davey Smith G, Munafo G, Relton MR, Richmond CL. Investigating the impact of cigarette smoking behaviours on DNA methylation patterns in adolescence. Hum Mol Genet. 2019;28:155–65.

    Article  CAS  PubMed  Google Scholar 

  18. Fasanelli F, Baglietto L, Ponzi E, Guida F, Campanella G, Johansson M, Grankvist K, Johansson M, Assumma MB, Naccarati A, Chadeau-Hyam M, Ala U, Faltus C, Kaaks R, Risch A, De Stavola B, Hodge A, Giles GG, Southey MC, Relton CL, Haycock PC, Lund E, Polidoro S, Sandanger TM, Severi G, Vineis P. Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts. Nat Commun. 2015;6:10192.

    Article  CAS  PubMed  Google Scholar 

  19. Bojesen SE, Timpson N, Relton C, Davey Smith G, Nordestgaard BG. AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality. Thorax. 2017;72:646–53.

    Article  PubMed  Google Scholar 

  20. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Huang MN, Tiang NG, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstorm EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V, Group, PMSW. Getz G Rozen, SG. Stratton, MR. Consortium, P. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Franceschi, S., El-serag, HB., Forman, D., Newton, R. Plummer, M. in Schottenfeld and Fraumeni cancer epidemiology and prevention (eds M. Thun et al.) Ch. 24, 433–460 (Oxford University Press, 2018).

  22. Kreimer AR, Ferreiro-Iglesias A, Nygard M, Bender N, Schroeder L, Hildesheim A, Robbins HA, Pawlita M, Langseth H, Schlecht NF, Tinker LF, Agalliu I, Smoller SW, Ness-Jensen E, Hveem K, D’Souza G, Visvanathan K, May B, Ursin G, Weiderpass E, Giles GG, Milne RL, Cai Q, Blot WJ, Zheng W, Weinstein SJ, Albanes D, Brenner N, Hoffman-Bolton J, Kaaks R, Barricarte A, Tjonneland A, Sacerdote C, Trichopoulou A, Vermeulen RCH, Huang WY, Freedman ND, Brennan P, Waterboer T, Johansson M. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. Ann Oncol. 2019;30:1335–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kreimer AR, Shiels MS, Fakhry C, Johansson M, Pawlita M, Brennan P, Hildesheim A, Waterboer T. Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. Cancer. 2018;124:1859–66.

    Article  PubMed  Google Scholar 

  24. Leung E, Han K, Zou J, Zhao Z, Zheng Y, Wang TT, Rostami A, Siu LL, Pugh TJ, Bratman SV. HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA. Clin Cancer Res. 2021;27:5857–68.

    Article  CAS  PubMed  Google Scholar 

  25. Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin. 2021;71:333–58.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69:184–210.

    Article  PubMed  Google Scholar 

  27. Tammemagi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2022;23:138–48.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF, Presept Clinical Study Steering Committee, I. & StudyT. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.

    Article  CAS  PubMed  Google Scholar 

  29. Heitzer E, Haque IS, Roberts CES, Speicher MR. Nat Rev Genet. 2019;20:71–88.

    Article  CAS  PubMed  Google Scholar 

  30. Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754–65.

    Article  CAS  PubMed  Google Scholar 

  31. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312.

    Article  PubMed  Google Scholar 

  32. Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553–67.

    Article  CAS  PubMed  Google Scholar 

  33. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383:650–63.

    Article  CAS  PubMed  Google Scholar 

  35. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, Samet Y, Maoz M, Druid H, Arner P, Fu KY, Kiss E, Spalding KL, Landesberg G, Zick A, Grinshpun A, Shapiro AMJ, Grompe M, Wittenberg AD, Glaser B, Shemer R, Kaplan T, Dor Y. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9:5068.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O’Kane GM, Liu J, Mansour M, McPherson JD, O’Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579–83.

    Article  CAS  PubMed  Google Scholar 

  37. Lo, Y. M. D., Han, D. S. C., Jiang, P. & Chiu, R. W. K. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science 372 (2021).

  38. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745–59.

    Article  CAS  PubMed  Google Scholar 

  39. Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, Jamshidi A, Kurtzman KN, Seiden MV, Swanton C, Liu MC. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167–77.

    Article  CAS  PubMed  Google Scholar 

  40. Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: a systematic review and meta-analysis. JAMA Oncol. 2019;5:e182815.

    Article  PubMed  Google Scholar 

  41. Ibrahim W, Carr L, Cordell R, Wilde MJ, Salman D, Monks PS, Thomas P, Brightling CE, Siddiqui S, Greening NJ. Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases. Thorax. 2021;76:514–21.

    Article  PubMed  Google Scholar 

  42. Wang L, Li J, Xiong X, Hao T, Zhang C, Gao Z, Zhong L, Zhao Y. Volatile organic compounds as a potential screening tool for neoplasm of the digestive system: a meta-analysis. Sci Rep. 2021;11:23716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Mehta D, Uber R, Ingle T, Li C, Liu Z, Thakkar S, Ning B, Wu L, Yang J, Harris S, Zhou G, Xu J, Tong W, Lesko L, Fang H. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine. Drug Discov Today. 2020;25:813–20.

    Article  PubMed  Google Scholar 

  45. Administration, U. F. a. D. Vol. 2022 (US Food and Drug Administration, 2021).

  46. Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019;197:122–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A. & Akbari, M. R. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel) 12 (2020).

  48. Dagnino S, Bodinier B, Guida F, Smith-Byrne K, Petrovic D, Whitaker MD, Haugdahl Nost T, Agnoli C, Palli D, Sacerdote C, Panico S, Tumino R, Schulze MB, Johansson M, Keski-Rahkonen P, Scalbert A, Vineis P, Johansson M, Sandanger TM, Vermeulen RCH, Chadeau-Hyam M. Prospective Identification of elevated circulating CDCP1 in patients years before onset of lung cancer. Cancer Res. 2021;81:3738–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nedjadi T, Benabdelkamal H, Albarakati N, Masood A, Al-Sayyad A, Alfadda AA, Alanazi IO, Al-Ammari A, Al-Maghrabi J. Circulating proteomic signature for detection of biomarkers in bladder cancer patients. Sci Rep. 2020;10:10999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Loriot Y, Marabelle A, Guegan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, Andre F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021;32:1381–90.

    Article  CAS  PubMed  Google Scholar 

  51. Rittmann MC, Hussung S, Braun LM, Klar RFU, Biesel EA, Fichtner-Feigl S, Fritsch R, Wittel UA, Ruess DA. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Sci Rep. 2021;11:7499.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lam MPY, Ge Y. Harnessing the power of proteomics to assess drug safety and guide clinical trials. Circulation. 2018;137:1011–4.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman AK, Schork A, Page K, Zhernakova DV, Wu Y, Peters J, Eriksson N, Bergen SE, Boutin TS, Bretherick AD, Enroth S, Kalnapenkis A, Gadin JR, Suur BE, Chen Y, Matic L, Gale JD, Lee J, Zhang W, Quazi A, Ala-Korpela M, Choi SH, Claringbould A, Danesh J, Davey Smith G, de Masi F, Elmstahl S, Engstrom G, Fauman E, Fernandez C, Franke L, Franks PW, Giedraitis V, Haley C, Hamsten A, Ingason A, Johansson A, Joshi PK, Lind L, Lindgren CM, Lubitz S, Palmer T, Macdonald-Dunlop E, Magnusson M, Melander O, Michaelsson K, Morris AP, Magi R, Nagle MW, Nilsson PM, Nilsson J, Orho-Melander M, Polasek O, Prins B, Palsson E, Qi T, Sjogren M, Sundstrom J, Surendran P, Vosa U, Werge T, Wernersson R, Westra HJ, Yang J, Zhernakova A, Arnlov J, Fu J, Smith JG, Esko T, Hayward C, Gyllensten U, Landen M, Siegbahn A, Wilson JF, Wallentin L, Butterworth AS, Holmes MV, Ingelsson E, Malarstig A. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab. 2020;2:1135–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B, Li C, Zhang L, Qin G, Zhang M, Chen N, Zhang M, Huang Y, Zhou J, Zhao Y, Liu M, Zhu X, Qiu Y, Sun Y, Huang C, Yan M, Wang M, Liu W, Tian F, Xu H, Zhou J, Wu Z, Shi T, Zhu W, Qin J, Xie L, Fan J, Qian X, He F. Chinese Human Proteome Project, C. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567:257–61.

    Article  CAS  PubMed  Google Scholar 

  55. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blazenovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569:723–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kwon YW, Jo HS, Bae S, Seo Y, Song P, Song M, Song P, Yoon JH. Application of proteomics in cancer: recent trends and approaches for biomarkers discovery. Front Med (Lausanne). 2021;8:747333.

    Article  Google Scholar 

  57. Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, Janjic N. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids. 2014;3:e201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9:e95192.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyo D, Ellis MJ, Carr SA, Nci C. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, McDermott JE, Clauss TR, Moore RJ, Zhao R, Monroe ME, Wang YT, Chambers MC, Slebos RJC, Lau KS, Mo Q, Ding L, Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B. Clinical proteomic tumor analysis, C proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035-1049 e1019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyo D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017;8:14864.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, Ellis MJ. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A. 2018;115:E11978–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV, Jensson BO, Zink F, Halldorsson GH, Masson G, Arnadottir GA, Katrinardottir H, Juliusson K, Magnusson MK, Magnusson OT, Fridriksdottir R, Saevarsdottir S, Gudjonsson SA, Stacey SN, Rognvaldsson S, Eiriksdottir T, Olafsdottir TA, Steinthorsdottir V, Tragante V, Ulfarsson MO, Stefansson H, Jonsdottir I, Holm H, Rafnar T, Melsted P, Saemundsdottir J, Norddahl GL, Lund SH, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712–21.

    Article  CAS  PubMed  Google Scholar 

  64. Pietzner M, Wheeler E, Carrasco-Zanini J, Cortes A, Koprulu M, Worheide MA, Oerton E, Cook J, Stewart ID, Kerrison ND, Luan J, Raffler J, Arnold M, Arlt W, O’Rahilly S, Kastenmuller G, Gamazon ER, Hingorani AD, Scott RA, Wareham NJ, Langenberg C. Mapping the proteo-genomic convergence of human diseases. Science. 2021;374:1541.

    Article  CAS  Google Scholar 

  65. Dulaney C, Wallace AS, Everett AS, Dover L, McDonald A, Kropp L. Defining health across the cancer continuum. Cureus. 2017;9:e1029.

    PubMed  PubMed Central  Google Scholar 

  66. Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003;13:248–66.

    Article  PubMed  Google Scholar 

  67. Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17:241–8.

    Article  CAS  PubMed  Google Scholar 

  68. Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin North Am. 2015;62:275–300.

    Article  PubMed  Google Scholar 

  69. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10:S4282–95.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, Getz KD, Armenian SH, Januzzi JL, Tang WHW, Liu P, Ky B. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc. 2020;9:e014708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Kawada M, Hirayama M, Tsuji Y. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. 2017;24:774–82.

    Article  PubMed  Google Scholar 

  72. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809–16.

    Article  CAS  PubMed  Google Scholar 

  73. Wang YD, Chen SX, Ren LQ. Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett. 2016;11:3483–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Pavo N, Raderer M, Hulsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Kostler W, Zochbauer-Muller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874–80.

    Article  CAS  PubMed  Google Scholar 

  76. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis. 2017;259:75–82.

    Article  CAS  PubMed  Google Scholar 

  77. Singh-Manoux A, Shipley MJ, Bell JA, Canonico M, Elbaz A, Kivimaki M. Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. CMAJ: Canadian Medical Assoc J =journal de l’Association medicale canadienne. 2017;189:E384–90.

    Article  Google Scholar 

  78. Gai W, An J, Wang Z, Han X, Geng J, Liang Y, Guo Y. Research progress of biomarkers in early detection of chemotherapy-induced cardiotoxicity. Heart Fail Rev. 2021;26:1195–201.

    Article  PubMed  Google Scholar 

  79. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020;13:431–50.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Tonorezos ES, Hudson MM, Edgar AB, Kremer LC, Sklar CA, Wallace WH, Oeffinger KC. Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer. Lancet Diabetes Endocrinol. 2015;3:545–55.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Feng Z, Pepe MS. Adding rigor to biomarker evaluations-EDRN experience. Cancer Epidemiol Biomarkers Prev. 2020;29:2575–82.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Meddeb R, Pisareva E, Thierry AR. Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem. 2019;65:623–33.

    Article  CAS  PubMed  Google Scholar 

  83. Korthauer K, Kimes PK, Duvallet C, Reyes A, Subramanian A, Teng M, Shukla C, Alm EJ, Hicks SC. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20:118.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Ou FS, Michiels S, Shyr Y, Adjei AA, Oberg AL. Biomarker discovery and validation: statistical considerations. J Thorac Oncol. 2021;16:537–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Diaz-Papkovich A, Anderson-Trocme L, Gravel S. A review of UMAP in population genetics. J Hum Genet. 2021;66:85–91.

    Article  PubMed  Google Scholar 

  86. Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW. Topic group “evaluating diagnostic, t. & prediction models” of the, S. i. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17:230.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.

    Article  PubMed  Google Scholar 

  88. Collins GS, Dhiman P, Andaur Navarro CL, Ma J, Hooft L, Reitsma JB, Logullo P, Beam AL, Peng L, Van Calster B, van Smeden M, Riley RD, Moons KG. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open. 2021;11:e048008.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Wand H, Lambert SA, Tamburro C, Iacocca MA, O’Sullivan JW, Sillari C, Kullo IJ, Rowley R, Dron JS, Brockman D, Venner E, McCarthy MI, Antoniou AC, Easton DF, Hegele RA, Khera AV, Chatterjee N, Kooperberg C, Edwards K, Vlessis K, Kinnear K, Danesh JN, Parkinson H, Ramos EM, Roberts MC, Ormond KE, Khoury MJ, Janssens A, Goddard KAB, Kraft P, MacArthur JAL, Inouye M, Wojcik GL. Improving reporting standards for polygenic scores in risk prediction studies. Nature. 2021;591:211–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18:500–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Fang Z, Ma T, Tang G, Zhu L, Yan Q, Wang T, Celedon JC, Chen W, Tseng GC. Bayesian integrative model for multi-omics data with missingness. Bioinformatics. 2018;34:3801–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Chu J, Sun NA, Hu W, Chen X, Yi N, Shen Y. The application of Bayesian methods in cancer prognosis and prediction. Cancer Genomics Proteomics. 2022;19:1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Brooks, J. D., Nabi, H. H., Andrulis, I. L., Antoniou, A. C., Chiquette, J., Despres, P., Devilee, P., Dorval, M., Droit, A., Easton, D. F., Eisen, A., Eloy, L., Fienberg, S., Goldgar, D., Hahnen, E., Joly, Y., Knoppers, B. M., Lofters, A., Masson, J. Y., Mittmann, N., Paquette, J. S., Pashayan, N., Schmutzler, R., Stockley, T., Tavtigian, S. V., Walker, M. J., Wolfson, M., Chiarelli, A. M. & Simard, J. Personalized risk assessment for prevention and early detection of breast cancer: integration and implementation (PERSPECTIVE I&I). J Pers Med 11 (2021).

  94. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17:687–705.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SKA. Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a diagnostic biomarker. JNCI Cancer Spectr. 2021;5:081.

    Article  Google Scholar 

  96. Winkler EC, Knoppers BM. Ethical challenges of precision cancer medicine. Semin Cancer Biol. 2022;84:263–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This work is supported by the Canadian Institute of Health Research Canada Research Chair to R. J. H and the National Institute of Heath (U19 CA203654).

Author information

Authors and Affiliations

  1. Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada

    Rayjean J. Hung, Elham Khodayari Moez & Sanjeev Budhathoki

  2. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

    Rayjean J. Hung, Shana J. Kim & Jennifer D. Brooks

Authors
  1. Rayjean J. Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elham Khodayari Moez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shana J. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sanjeev Budhathoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer D. Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rayjean J. Hung.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Genetic Epidemiology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hung, R.J., Khodayari Moez, E., Kim, S.J. et al. Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine. Curr Epidemiol Rep 9, 200–211 (2022). https://doi.org/10.1007/s40471-022-00295-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40471-022-00295-8

Keywords

Search

Navigation